Maintenance. We are currently updating the site. Please check back shortly

Thomson Reuters Foundation

Inform - Connect - Empower

Founder of scandal-hit drugmaker Servier dies at 92

Source: Reuters - Thu, 17 Apr 2014 08:16 GMT
Author: Reuters
hum-dis
Tweet Recommend Google + LinkedIn Email Print
Leave us a comment

PARIS, April 17 (Reuters) - Jacques Servier, founder and president of France's second-largest drugmaker, has died before his trial over Mediator, a weight-loss pill at the centre of the country's biggest public health scandal in years.

The 92-year-old billionaire doctor, who founded the privately held drugmaker that bears his name 60 years ago, died on Wednesday at his home, the company said late that evening.

Servier died of old age, a company spokeswoman said on Thursday.

He was placed under investigation in 2012 on suspicion of manslaughter for his role in the Mediator scandal and had always denied any wrongdoing.

A trial is expected in the first half of 2015 to determine whether the company misled patients and authorities about the pill, suspected of causing heart-valve disorders.

Officials have blamed at least 500 deaths on Mediator, which was marketed to overweight diabetics but often prescribed for weight loss. The drug was pulled from the French market in 2009, about a decade after its withdrawal from Spain, Italy and the United States.

Servier posted revenue of 4.2 billion euros ($5.8 billion) in 2013, making it France's second-biggest drugmaker by sales behind Sanofi. The fortune of Servier's founder was estimated at 2.3 billion euros by economic magazine Challenges.

($1 = 0.7243 Euros)

(Reporting by Natalie Huet; Editing by Erica Billingham)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of the Thomson Reuters Foundation. For more information see our Acceptable Use Policy.

comments powered by Disqus